New science, in plain language. Checked before you read a word.

Every two days we take 10 brand-new scholarly papers, screen each one for retractions and a live DOI, and rewrite them so a curious person can actually read them.

This screen checks process signals. It does not tell you the findings are true.

Get it free, every two days

Three papers free every issue. No spam. Leave in one click.

In this issue 10 papers · 3 free

01 Nature Medicine Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial Free
02 Nature Communications Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer Free
03 Proceedings of the National Academy of Sciences Divergent population trajectories despite similar response to temperature in a widespread aerial insectivore Free
04 Proceedings of the National Academy of Sciences Cell competition overcomes host tissue resistance to unleash tumor growth in a Drosophila brain cancer model Subscribers
05 Nature Human Behaviour Active vision is linked to category selectivity in the individual brain Subscribers
06 Nature Climate Change Future-proofing interpretations of the Paris Agreement’s limit of well below 2 °C Subscribers
07 Nature Communications Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation Subscribers
08 Nature Human Behaviour Stable intuition and the rise of deliberative prosociality in childhood Subscribers
09 Science Alternating atomic-dipole layers and switching dynamics in Al 1-x Sc x N ferroelectrics Subscribers
10 Science Orbital magnetoresistance in the antiferromagnet CoO driven by dynamic orbital angular momentum Subscribers

The papers Read free

Nature Medicine·7 July 2026

Deborah A. Theodore, Bryan T. Mayer et al.

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial

A new lab-made antibody for HIV showed no serious safety problems in its first human trial. This antibody attaches to two different targets at once. One part sticks to the virus. The other part sticks to a protein on human immune cells. Doctors tested it in 54 people, some with HIV and some without, using shots or IV drips at different doses. The most common side effects were soreness where the shot went in, tiredness, and headache. Three out of nine people with HIV got a body rash about 8 to 12 days after treatment. The rash went away within 9 to 16 days.

A double-acting HIV antibody was safe and well tolerated in its first human trial.

The number: Fatigue was the most common side effect, affecting 18 of 54 participants (33.3%).
The caveat: This trial only tested 54 people and only checked safety and dosing. It cannot show how well the antibody actually prevents or treats HIV over time.

For your life: nothing to act on yet. Early research, worth watching.

Integrity screen: passed (3 checks) Checked 8 July 2026. Retraction record: none. DOI resolves at doi.org. Metadata record found (Nature Medicine). Read the source

Nature Communications·8 July 2026

Scott Best, Daniel S. Hippe et al.

Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer

Small cell lung cancer often shrinks fast with chemotherapy. But it usually comes back in a harder to treat form. Scientists searched genes in tumor samples grown in mice to find out why. They found that losing one gene, called USP22, helps tumors resist chemotherapy. Tumors without this gene also relied more on burning sugar for energy. Blocking a sugar carrier made those resistant tumors sensitive to chemotherapy again.

Losing one gene lets lung cancer tumors resist chemotherapy, but blocking sugar uptake reverses this.

The number: No key statistic identified
The caveat: This work used tumor samples grown in mice, not human patients. It cannot yet show whether blocking sugar uptake would help people with resistant lung cancer.

For your life: nothing to act on yet. Early research, worth watching.

Integrity screen: passed (3 checks) Checked 8 July 2026. Retraction record: none. DOI resolves at doi.org. Metadata record found (Nature Communications). Read the source

Proceedings of the National Academy of Sciences·7 July 2026

Conor C. Taff, J. Ryan Shipley et al.

Divergent population trajectories despite similar response to temperature in a widespread aerial insectivore

Tree swallows across North America all respond to warm weather in the same way. Every population lays eggs about one day earlier for each degree the temperature rises. But northern birds are hit harder by climate change than southern birds. Northern populations have shifted their nesting earlier the most, since they warmed up the most. Even so, they still feel strong pressure to nest earlier, especially in warm years. These northern groups have also lost the most birds over time.

Northern swallow populations shifted nesting earliest but still lost the most birds.

The number: Across 1,555 population-years from 123 populations, all populations advanced breeding by about one day per degree of warming.
The caveat: This study looked at patterns linking temperature, timing, and bird numbers. It cannot prove that timing problems alone caused the population drops.

For your life: today, nothing. This is basic research.

Integrity screen: passed (3 checks) Checked 8 July 2026. Retraction record: none. DOI resolves at doi.org. Metadata record found (Proceedings of the National Academy of Sciences). Read the source

7 more papers are in the full issue.

The same screening, the full reading, every two days. 2 euros a month, or 20 a year, and you can leave in one click.

Proceedings of the National Academy of Sciences·7 July 2026

Marco Gualtieri, Saline Jabre et al.